Budget impact of switching from an immediate-release to a prolonged-release formulation of tacrolimus in renal transplant recipients in the UK based on differences in adherence

BACKGROUND AND AIMS: Advagraf is a once-daily prolonged-release formulation of tacrolimus with proven noninferiority to Prograf, a twice-daily immediate-release formulation of tacroli-mus, in biopsy-proven acute rejection, graft survival and patient survival in renal transplant recipients. Advagraf...

Descripción completa

Detalles Bibliográficos
Autores principales: Muduma, Gorden, Odeyemi, Isaac, Smith-Palmer, Jayne, Pollock, Richard F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3974691/
https://www.ncbi.nlm.nih.gov/pubmed/24729687
http://dx.doi.org/10.2147/PPA.S60213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3974691/
https://www.ncbi.nlm.nih.gov/pubmed/24729687
http://dx.doi.org/10.2147/PPA.S60213

Ejemplares similares